Loading...
OTCMNWBO
Market cap337mUSD
Dec 24, Last price  
0.26USD
1D
-2.86%
1Q
-20.80%
Jan 2017
-25.26%
Name

Northwest Biotherapeutics Inc

Chart & Performance

D1W1MN
OTCM:NWBO chart
P/E
—
P/S
174.67
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
20.53%
Rev. gr., 5y
36.21%
Revenues
2m
+14.80%
390,000124,000800,00010,00010,00010,00010,00010,000772,000809,0001,454,0001,739,000623,000336,000412,0002,410,0001,291,0001,005,0001,683,0001,932,000
Net income
-63m
L-54.26%
-8,508,000-9,937,000-1,395,000-21,257,000-22,331,000-25,271,000-27,368,000-32,830,000-67,320,000-65,789,000-135,634,000-114,741,000-80,214,000-73,143,000-35,794,000-23,572,000-538,365,000179,126,000-136,848,000-62,599,000
CFO
-54m
L+1.63%
-4,425,000-4,184,000-6,930,000-14,601,000-15,587,000-4,677,000-6,376,000-14,707,000-22,754,000-37,800,000-54,576,000-78,608,000-55,652,000-36,495,000-34,586,000-31,859,000-32,093,000-38,299,000-52,775,000-53,637,000
Earnings
Mar 03, 2025

Profile

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
URL
https://nwbio.com/
IPO date
Dec 14, 2001
Employees
22
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,932
14.80%
1,683
67.46%
1,005
-22.15%
Cost of revenue
85,170
70,412
74,015
Unusual Expense (Income)
NOPBT
(83,238)
(68,729)
(73,010)
NOPBT Margin
Operating Taxes
31,816
4,364
Tax Rate
NOPAT
(83,238)
(100,545)
(77,374)
Net income
(62,599)
-54.26%
(136,848)
-176.40%
179,126
-133.27%
Dividends
Dividend yield
Proceeds from repurchase of equity
15,047
39,291
4,070
BB yield
-1.92%
-4.93%
-0.58%
Debt
Debt current
21,108
15,892
7,556
Long-term debt
29,534
15,085
35,925
Deferred revenue
Other long-term liabilities
4,950
23,060
Net debt
48,516
23,933
28,233
Cash flow
Cash from operating activities
(53,637)
(52,775)
(38,299)
CAPEX
(3,437)
(2,902)
(6,015)
Cash from investing activities
(3,437)
(2,902)
(6,015)
Cash from financing activities
52,758
41,968
48,132
FCF
(165,781)
(108,499)
(334,243)
Balance
Cash
2,126
6,965
15,169
Long term investments
79
79
Excess cash
2,029
6,960
15,198
Stockholders' equity
(1,338,292)
(1,269,849)
(1,190,785)
Invested Capital
1,342,061
1,191,059
1,104,732
ROIC
ROCE
87.23%
84.84%
EV
Common stock shares outstanding
1,119,191
1,015,852
1,007,869
Price
0.70
-10.64%
0.78
12.07%
0.70
-54.10%
Market cap
784,553
-1.55%
796,936
12.96%
705,508
-36.20%
EV
851,787
843,929
733,741
EBITDA
(81,505)
(67,229)
(72,424)
EV/EBITDA
Interest
5,241
6,068
5,011
Interest/NOPBT